+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neurotrophic Keratitis Market (2022-2027) by Route of Administration, Distribution Channel, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis

  • PDF Icon

    Report

  • 179 Pages
  • July 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5650830

In 2022, The FDA approved Italian firm Dompé’s eye drop Oxervate for the treatment of neurotrophic keratitis (NK)

The Global Neurotrophic Keratitis Market is estimated to be worth USD 191.1 million in 2022, and is expected to reach USD 439.05 million by 2027, growing at a CAGR of 18.1%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals. As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentation

The Global Neurotrophic Keratitis Market is segmented based on Route of Administration, Distribution Channel, and Geography.
  • By Route of Administration, the market is classified into Injection, Oral, Topical.
  • By Distribution Channel, the market is classified into Drug Stores and Hospitals.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Alvogen , Aurolab , Bausch Health , Eyevance , Gilead Biosciences , Glenmark , Leadiant Biosciences , Merck , Novo Holdings , Pfizer, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Neurotrophic Keratitis Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The Global Neurotrophic Keratitis Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Why Buy This Report?

  • The report offers a comprehensive evaluation of the Global Neurotrophic Keratitis Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario within the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.
  • The report also contains competitive analysis using 'Positioning Quadrants'; a proprietary competitive positioning tool.

Report Highlights

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Neurotrophic Keratitis Market

What is the estimated value of the Global Neurotrophic Keratitis Market?

The Global Neurotrophic Keratitis Market was estimated to be valued at $191.1 Million in 2022.

What is the growth rate of the Global Neurotrophic Keratitis Market?

The growth rate of the Global Neurotrophic Keratitis Market is 18.1%, with an estimated value of $439.05 Million by 2027.

What is the forecasted size of the Global Neurotrophic Keratitis Market?

The Global Neurotrophic Keratitis Market is estimated to be worth $439.05 Million by 2027.

Who are the key companies in the Global Neurotrophic Keratitis Market?

Key companies in the Global Neurotrophic Keratitis Market include Alvogen, Aurolab, Bausch Health, Eyevance, Gilead Biosciences, Glenmark, Leadiant Biosciences, Merck and Pfizer.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Proprietary Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Visual Impairment Due to Fungal Keratitis
4.1.2 Increasing Number of Fungal Keratitis in Regions with Mild Temperature Climates
4.1.3 Number of Contact Lens Wearers Has Been Increased, and Do Not Follow Directions for Proper Care of Contact Lenses
4.2 Restraints
4.2.1 Non-Availability of Antifungal Recommendations with Specific Fungal Isolation
4.3 Opportunities
4.3.1 Aggressive Topical Antifungal Therapy for the Treatment
4.3.2 New Product Developments in the Treatments of Fungal Keratitis
4.4 Challenges
4.4.1 Rising Number of Failed Medical Surgeries in a Reappearance of Fungus
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Neurotrophic Keratitis Market, by Route of Administration
6.1 Introduction
6.2 Injection
6.3 Oral
6.4 Topical
7 Global Neurotrophic Keratitis Market, by Distribution Channel
7.1 Introduction
7.2 Drug Stores
7.3 Hospitals
8 Americas' Neurotrophic Keratitis Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe's Neurotrophic Keratitis Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Italy
9.9 Netherlands
9.10 Norway
9.11 Poland
9.12 Russia
9.13 Spain
9.14 Sweden
9.15 Switzerland
9.16 United Kingdom
9.17 Rest of Europe
10 Middle East and Africa's Neurotrophic Keratitis Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Saudi Arabia
10.6 South Africa
10.7 United Arab Emirates
10.8 Rest of MEA
11 APAC's Neurotrophic Keratitis Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
12.3.1 M&A and Investments
12.3.2 Partnerships and Collaborations
12.3.3 Product Developments and Improvements
13 Company Profiles
13.1 Alvogen
13.2 Aurolab
13.3 Bausch Health
13.4 Eyevance
13.5 Gilead Biosciences
13.6 Glenmark
13.7 Leadiant Biosciences
13.8 Merck
13.9 Novo Holdings
13.10 Pfizer
14 Appendix
14.1 Questionnaire

Companies Mentioned

  • Alvogen
  • Aurolab
  • Bausch Health
  • Eyevance
  • Gilead Biosciences
  • Glenmark
  • Leadiant Biosciences
  • Merck
  • Novo Holdings
  • Pfizer